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Supplemental Data Titles and Legends 1 
2 
Figure S1. Related to Figure 1.  Hepatic vagotomy did not affect body mass (A), percent fat mass (B), or 3 
percent lean mass (C) in adult male mice on a chow diet and after 9 weeks on a high fat diet. Number 4 




Figure S2. Related to Figure 2. Immunohistochemical validation of liver specific viral induced PSEM89S 7 
ligand gated depolarizing channel (A-B; 10X magnification). Skeletal muscle (Sk. Muscle), pancreas, and 8 
adipose tissue from an albumin-cre expressing mouse tail-vein injected with an AAV8 encoding for the 9 
PSEM89S ligand activated depolarizing channel and green fluorescent protein (GFP) whose expression is 10 
dependent on cre-recombinase (A). Skeletal muscle (Sk. Muscle), pancreas, and adipose from a wildtype 11 
mouse tail-vein injected with an AAV8 encoding the PSEM89S ligand activated depolarizing channel and 12 
GFP whose liver specific expression is driven by the thyroxine binding globulin (TBG) promoter (B). GFP 13 
positive cells in the liver of a wildtype mouse tail-vein injected with the TBG virus co-stain with arginase-14 
1 (C-E; 20X magnification). Staining for GFP (C), the hepatocyte specific marker arginase-1 (D), and 15 
double labeling of GFP and arginase-1 (E; arrows indicate co-staining). No primary control imaged at the 16 




Figure S3. Related to Figure 3. Hepatic Kir2.1 expression alters glucose homeostasis in the lean mouse. 19 
Hepatic Kir2.1 expression effects on serum insulin (A) glucose (B), glucose:insulin ratio (C), oral glucose 20 
tolerance (OGTT; D), OGTT area under the curve (AUC; E), oral glucose stimulated serum insulin (F; * 21 
denotes significance (P < 0.05) between bars of the same color), insulin tolerance (ITT; G) ITT AUC (H), 22 
pyruvate tolerance (PTT; I), and PTT AUC (J). NS = non-significant. Number below bar denotes n per 23 






Figure S4. Related to Figure 3. Glucose homeostasis in Kir2.1 and eGFP control mice at 3 weeks of high 28 
fat diet feeding. Effect of hepatic Kir2.1 expression on oral glucose tolerance (OGTT; A), OGTT area under 29 
the curve (AUC; B), oral glucose stimulated serum insulin (C), insulin tolerance (ITT; D), and ITT AUC 30 
(E). NS = non-significant. Number below bar denotes n per group. All data are presented as mean ± SEM. 31 




Figure S5. Related to Figure 6. Immunohistochemical evidence of GABAA receptor expressing vagal 34 
afferent innervation in the liver. Staining for the vagal afferent marker calretinin (A) and GABAA receptors 35 
(B) which correspond with the co-labeled image in Fig. 6A. No primary control imaged at the same settings 36 
as Fig. 6A (C). Staining for the alternative vagal afferent marker calcitonin gene-related peptide (CGRP; 37 
D) and GABAA receptors (E) which correspond with the co-labeled image in Fig. 6C. No primary control 38 
imaged at the same settings as Fig. 6C (F). Blue = DAPI (nucleus). Images at 10X magnification. BV = 39 
blood vessel 40 




Figure S6. Related to Figure 6. Immunohistochemical evidence that hepatic vagotomy decreases 43 
immunohistochemical staining for 2 vagal afferent markers (green), calcitonin gene related 44 
peptide (CGRP; A-D) and calretinin (E-H).  GABAA receptor is labeled in red.  All images, 45 
including no-primary controls (I and J) were collected with identical settings. Blue = DAPI 46 
(nucleus). Images at 10 and 20X magnification as labelled. 47 




Figure S7. Related to Figures 1 and 3. Insulin tolerance tests (ITT) presented as raw 50 
glucose values. ITT in HFD fed sham and vagotomized mice (A). ITT in Kir2.1 and 51 
eGFP control mice on chow diet (B), and after 3 (C), and 9 weeks of HFD feeding (D).  52 
† Denotes the data point is not significantly different from time 0 for that group (P > 53 
0.05). Unless indicated, all other timepoints are significantly different from time 0 54 
within a group of mice. * Denotes significance between groups specified in the panel 55 
within a timepoint. All data are presented as mean ± SEM.  56 




Figure S8.  Related to Figure 2. Raw signal generated from vagal nerve recordings including ECG signal 59 
and breathing artifacts.  Data was filtered to remove these signals that are not specific to vagal nerve 60 
activity and the signal rectified to allow for integration of total nerve bundle activity.  Top to bottom 61 
includes more zoomed in versions of the timeline to allow the reader to understand exactly what was 62 
analyzed.    63 
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Lean (N = 5) 
 
Obese (N = 3) 
% Change 
in Obesity 
Adenosine 0.22 ±0.04 0.10 ± 0.01 -55%* 
 
Histidine 17.74 ± 0.92 12.90 ± 0.72 -27%* 
 
Serine 22.32 ± 3.33 13.02 ± 0.53 -42% 
 
Taurine 238.40 ± 18.41 305.18 ± 38.04 28% 
 
Glutamine 49.06 ± 5.19 40.39 ± 3.98 -17% 
 
Glycine 130.74 ± 5.16 81.31 ± 4.93 -37%* 
 
Aspartic Acid 6.92 ± 0.55 3.47 ± 0.32 -50%* 
 
Glutamic Acid 30.32 ± 2.12 28.74 ± 3.48 -5.2% 
 
GABA 5.43 ± 0.64 8.77 ± 0.53 61%* 
 65 
Initial neuromodulators panel analysis on media collected form the liver 66 
explant studies performed by the Mayo Clinic Metabolomics Regional 67 
Core. *Indicates significant difference between obese and lean mice 68 
(P<0.05). Data are presented as mean ± SEM. 69 
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Table S2. Metabolic characteristics of the study subjects (n=19). Related to Figure 7. 70 
FFM, fat free mass; Glucose Rd, glucose disposal rate.  71 
 Mean ± SEM Range 
Body mass index (kg/m2) 45.1 ± 1.3 35.9 - 55.6 
Intrahepatic triglyceride content (%) 11.4 ± 1.9 2.7 - 28.0 
Glucose (mg/dL) 97 ± 2 81 - 121 
Insulin (μU/mL) 24.1 ± 1.7 13.1 - 46.5 
Glucose infusion rate during insulin infusion (μmol/kg FFM/min) 36.0 ± 3.0 15.2 - 60.8 
Glucose Rd during insulin infusion (% increase) 131 ± 19 30 - 355 
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Table S3. Related to Figure 7. Regression coefficient estimates showing 72 
the association between hepatic mRNA expression of genes involved in 73 
GABA production (ABAT) and GABA transport (Slc6A6, A8, A12, and 74 
A13) and glucose infusion rate (μMol/Kg Fat Free Mass/min) and 75 
Glucose Rd (rate of disposal; % increase) during a hyperinsulinemic-76 
euglycemic clamp. 77 
Glucose Infusion Rate (μMol/Kg Fat Free Mass/min) 
  Estimate SEM Lower CI Upper CI P- Value 
Intercept -36.41 53.75 -158.00 85.18 0.5152 
IHTG (%) -0.50 0.19 -0.92 -0.08 0.0242 
SLC6A12 13.80 5.72 0.86 26.74 0.0391 
SLC6A13 10.74 4.18 1.28 20.20 0.0302 
SLC6A6 -15.63 3.20 -22.87 -8.38 0.0009 
SLC6A8 -5.65 1.95 -10.07 -1.23 0.0179 
ABAT -3.26 7.04 -19.20 12.67 0.6545 
  
Glucose Rd During Insulin Infusion (% Increase) 
  Estimate SEM Lower CI Upper CI P- Value 
Intercept -3.91 4.24 -13.49 5.68 0.3805 
IHTG (%) -0.03 0.01 -0.07 0.00 0.0427 
SLC6A12 1.02 0.45 0.00 2.04 0.0505 
SLC6A13 0.64 0.33 -0.10 1.39 0.0834 
SLC6A6 -0.71 0.25 -1.28 -0.14 0.0204 
SLC6A8 -0.45 0.15 -0.79 -0.10 0.0178 
ABAT -0.24 0.56 -1.50 1.01 0.6712 
  78 
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Table S4. Related to Figure 7. Single nucleotide polymorphisms (SNPs) that result in missense mutations in GABA transporters are associated with 
an increased incidence (OR; odds ratio) of type 2 diabetes (T2D; source: knowledge portal diabetes database). MAF – minor allele frequency. 
SLC6A12 - T2D Associated SNPs 
Variant ID dbSNP ID Predicted Impact Study P-value Effect OR MAF 
12_313839_G_A rs188610 Missense: synonymous variant 
AMP T2D-GENES T2D exome sequence 
analysis 0.0238 ↑ 1.1 0.0386 
12_313824_G_A rs199521597 Missense: early stop codon BioMe AMP T2D GWAS 0.0409 ↑ 15.8 0.000269 
  
SLC6A13 - T2D Associated SNPs 
Variant ID dbSNP ID Predicted Impact Study P-value Effect OR MAF 
12_330193_C_T rs61741313 
Missense: Replaces Arganine with 
Glutamine 
DIAMANTE (European) T2D 




SLC6A6 -T2D Associated SNPs 
Variant ID dbSNP ID Predicted Impact Study P-value Effect OR MAF 
3_14489107_G_A rs62233560 
Missense: Replaces Valine with 
Isoleucine 
AMP T2D-GENES T2D exome sequence 




Missense: Replaces Valine with 




SLC6A12 - T2D Adjusted for BMI Associated SNPs 
Variant ID dbSNP ID Predicted Impact Study P-value Effect OR MAF 
12_302492_C_G rs138178078 
Missense:  Replace Tryptophan 
with Serine ExTexT2D exome chip analysis 0.000071 ↑ 1.26 0.0052 
12_319125_A_G rs557881 
Missense:  Replace Cysteine with 
Arginine ExTexT2D exome chip analysis 0.0396 ↑ 1.01 0.48 
12_300248_C_G,T rs147574089 
Missense:  Replace Glutamate with 
Glutamine CAMP GWAS 0.0397 ↑ 6.09 0.0012 
  
SLC6A13 - T2D Associated SNPs 
Variant ID dbSNP ID Predicted Impact Study P-value Effect OR MAF 
12_346454_C_T rs140951084 
Missense in Splice Region:  
Replace Arginine with Glutamine BioMe AMP T2D GWAS 0.0359 ↑ 3.55 0.0019 
 
